VIVOS INC - RDGL STOCK NEWS

Vivos Inc. (OTCQB: RDGL) has streamlined the IsoPet® therapy process by consolidating treatments into a single production run, effectively lowering production and shipping costs. This initiative was demonstrated at Johns Hopkins University, where two cats were treated using this new approach. Dr. Korenko emphasized the company's commitment to reducing costs while maintaining treatment quality for pets. Vivos' IsoPet® and RadioGel™ technologies use localized radiation for treating tumors in animals and humans, respectively, highlighting their innovation in the veterinary oncology space.

Vivos Inc. (OTCQB: RDGL) has successfully filed a particle patent in multiple countries, including the USA, EU, Japan, and others, enhancing its intellectual property strategy. The company is set to file a new utility patent for its hydrogel component later this year. This move underpins Vivos's plans to establish exclusive licensing agreements globally. Vivos has developed innovative brachytherapy treatments using Yttrium-90 for tumors in animals and humans, with its products aiming to offer effective radiation therapy while minimizing side effects.

Vivos Inc. (OTCQB: RDGL) provided a recap of its 2021 progress and future objectives. The company highlighted advancements in its IsoPet® animal therapy, including successful treatments and the formation of new regional clinics. For human therapy, RadioGel™ is undergoing FDA processes, with an upgraded Quality Management System in place. Challenges from the COVID-19 pandemic have been addressed, significantly improving hydrogel production efficiency. Financially, the company reports a strong capital structure with no toxic debt.

Vivos Inc. (OTCQB: RDGL) recently met with the FDA to discuss the Investigational Device Exemption for its RadioGel™ treatment for recurrent thyroid cancer. The FDA provided beneficial guidance, suggesting a Q-Submission path for expedited review and offering insights on clinical testing protocols. Vivos's representatives from Mayo Clinic effectively communicated the medical necessity for RadioGel™. CEO Mike Korenko noted that this pivotal meeting could prevent a rejected IDE submittal, emphasizing the company's readiness to cover costs for final IDE submission.

Vivos Inc. (OTCQB: RDGL) has announced a partnership with the Johns Hopkins Veterinary Clinical Trials Network for the Isopet® initiative, aimed at conducting animal studies on specific cancers. This collaboration is expected to enhance data collection for publishing in leading journals, thereby increasing awareness and acceptance of Isopet® within the veterinary oncology community. The Isopet® technology, based on yttrium-90, targets tumor treatment in animals and parallels the human treatment method, Radiogel™. The company aims to expand its regional centers and establish a robust presence in the veterinary market.

Vivos Inc. (OTCQB: RDGL) has announced that Johns Hopkins University is now an Isopet® regional clinic, which will conduct new studies on various cancers. This collaboration aims to generate high-quality data for publication, enhancing awareness within the veterinary oncology community. The Isopet® device, based on Yttrium-90, is designed to treat animal tumors effectively and can drive revenue through sales to veterinary hospitals and clinics. The FDA confirmed Isopet® as a medical device in 2018, streamlining its market introduction.

Vivos Inc. (OTCQB: RDGL) has signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow, New York, to establish an IsoPet regional therapy center. This center will focus on treating cancerous tumor margins post-surgery, potentially extending pet lives. Following the acquisition of a radioactive material handling license and necessary training, the center aims to expand its capabilities to treat other solid tumors. The initiative is backed by the Veterinary Medicine Advisory Board, led by Dr. Mike Korenko.

Vivos Inc. (OTCQB: RDGL) has successfully developed nine certification training modules in collaboration with FX Masse, aimed at establishing regional clinics for IsoPet therapy. These modules, now available on the FX Masse website, facilitate a flexible learning environment for new clinics before hands-on training. The training process will be linked to handling licenses for radioactive materials. With the usage of innovative hydrogel technology, Vivos Inc. delivers targeted radiation therapy for tumors in both animals and humans, enhancing treatment safety and efficacy.

Vivos Inc. (OTCQB: RDGL) announced the submission of its Investigational Device Exemption (IDE) for the Early Feasibility Medical Device Study of Y-90 RadioGel™ to the FDA. This marks a significant milestone, encouraging enhanced communication and an efficient review process. The IDE includes the Mayo Clinic's Clinical Trial Protocol. Dr. Mike Korenko noted FDA support for the project. RadioGel™ aims to treat tumors using localized radiation, reducing side effects associated with traditional therapies. This IDE submission signals Vivos's progress in cancer treatment innovation.